Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Current Deferred Revenue (2020 - 2025)

Bolt Biotherapeutics' Current Deferred Revenue history spans 6 years, with the latest figure at $1.9 million for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 3.15% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $1.9 million, down 3.15%, while the annual FY2024 figure was $3.0 million, 36.98% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $1.9 million at Bolt Biotherapeutics, down from $2.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $5.2 million in Q3 2021 and bottomed at $1.5 million in Q1 2021.
  • The 5-year median for Current Deferred Revenue is $2.5 million (2024), against an average of $2.7 million.
  • The largest annual shift saw Current Deferred Revenue soared 129.56% in 2022 before it tumbled 53.6% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $2.9 million in 2021, then tumbled by 30.53% to $2.0 million in 2022, then grew by 10.44% to $2.2 million in 2023, then skyrocketed by 36.98% to $3.0 million in 2024, then tumbled by 36.68% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Current Deferred Revenue are $1.9 million (Q3 2025), $2.5 million (Q2 2025), and $3.1 million (Q1 2025).